HIV Drug Resistance Mutations in Patients with HIV and HIV-TB Coinfection After Failure of First-Line Therapy: A Prevalence Study in a Resource-Limited Setting.
PMID: 31117863
2019
Journal of the International Association of Providers of AIDS Care
Abstract: M184V, M41L, D67N, G190A, A98G, and K103N were the most common mutations seen.
Table: K103N
Detection of human immunodeficiency virus Type 1 phylogenetic clusters with multidrug resistance mutations among 2011 to 2017 blood donors from the highly endemic Northern Brazilian Amazon.
Discussion: In a previous pre-treatment HIV-DR study, NNRTI resistance was K103N, Y181C, Y188C and G190A, and NRTI resistance was V75M and M184V.
HIV-1 drug resistance surveillance among parturient women on anti-retroviral therapy in the Eastern Cape, South Africa: Implications for elimination of mother-to-child transmission.
Abstract: Among the parturient women on EFV-based regimen treatment; 79.1% already had K103 N while nine patients on protease inhibitor-based regimen still harboured K103 N.
Abstract: The predominant DRMs were K103 N (n = 43; 74.1%), M184 V (n = 28; 48.3%) and K65R (n = 11; 19%).
Rates of HIV-1 virological suppression and patterns of acquired drug resistance among fisherfolk on first-line antiretroviral therapy in Uganda.
PMID: 31257432
2019
The Journal of antimicrobial chemotherapy
Abstract: The most prevalent mutations were M184V/I (53.6%) for NRTIs and K103N (39.2%) for NNRTIs.
Result: The most prevalent NNRTI mutations were K103N (39.2%), Y181C (19.6%) and G190A (15.5%) (Figure 3).
Discussion: All individuals with ADR had NNRTI mutations with K103N/S, Y181C, K101E/Q and G190S/A being more prevalent, depicting extensive use of the NNRTIs nevirapine and efavirenz in first-line regimens in this setting.
Sustained virological response and drug resistance among female sex workers living with HIV on antiretroviral therapy in Kampala, Uganda: a cross-sectional study.
Abstract: HIV resistance testing was available for 78% (28/38), of whom 82.1% (23/28) had at least one major drug resistance mutation (DRM), most frequently M184V (70%, 16/23) and K103N (65%, 15/23).
Introduction: The lamivudine (3TC, an NRTI drug) mutation M184V and the efavirenz (EFV) and nevirapine (NVP) (two NNRTI drugs) mutations K103N and 181C are frequently observed in cases of virological failure.
Result: The predominant mutations were M184V16 (70%) and K103N 15 (65%).
Discussion: Furthermore, consistent with findings from Rwanda, the most predominant mutations observed in this study were M184V for NRTI and K103N
HIV-1 Drug Resistance Mutations among Antiretroviral Drug-Experienced Patients in the South of Iran.
Abstract: M184V (40.9%) and K103N (25%), respectively related to NRTI and nonnucleoside reverse-transcriptase inhibitor (NNRTI), were the mutations with the highest frequencies.
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
PMID: 31430369
2019
The Journal of antimicrobial chemotherapy
Method: Primary NNRTI-R substitutions were L100I, K101E/P, K103N/S, V106M/A, V108I, E138A/G/K/Q/R, V179L, Y181C/I/V, Y188C/H/L, G190A/E/Q/S, H221Y, P225H, F227C and M230L/I in RT.
Result: NNRTI-R substitutions were observed in 23% (124/543) of participants; the most frequently detected substitutions w
HIV mutation literature information.
PMID: 
2019
Journal of the International Association of Providers of AIDS Care
Browser Board
Co-occurred Entities
Filtrator
ViMRT